EGFR mutations, ALK translocations, ROS1 aberrations and BRAF mutations are now routinely evaluated in advanced non-small cell lung cancer (NSCLC), especially in adenocarcinoma. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.